Blanks
Amie Blanks, Clemmons, NC US
Patent application number | Description | Published |
---|---|---|
20140100153 | PRE-SOAK TECHNOLOGY FOR LAUNDRY AND OTHER HARD SURFACE CLEANING - The invention relates to methods and compositions that may be used in a pre-soak system which maintains whitening and eliminates concerns of chlorine stability. The compositions and methods may be used for laundry, toilet bowl cleaners, ware wash cleaners, floor cleaners and the like. The system and compositions are particularly suited for laundry in a pre-soak system that includes the use of a “strainer” or basket for accomplishing the pre-soak step. Heavier soils fall to the bottom of the receptacle while greasy soils float to the top. | 04-10-2014 |
Bari G. Blanks, Belle Chasse, LA US
Patent application number | Description | Published |
---|---|---|
20140369768 | Interconnecting Members and Methods of Interconnecting Units - Connector plates having improved protrusions with flat surfaces facing lateral forces to increase stability and strength. Top flat surfaces are aligned with the back edge of the plate and bottom flat surfaces are aligned with the front edge of the plate. The connector plates may be used to install or erect a retaining wall, containment system, levy or a similar structure. The connector plates may have spike apertures allowing for the installation of additional spikes to further increase strength and resistance to lateral forces. | 12-18-2014 |
Durrell R. Blanks, Newport News, VA US
Patent application number | Description | Published |
---|---|---|
20160086372 | Three Dimensional Targeting Structure for Augmented Reality Applications - A method is provided for obtaining AR information for display on a mobile interface device. The method comprises placing a three dimensional targeting structure in a target space, the targeting structure comprising a plurality of planar, polygonal facets each having a unique target pattern applied thereto. A position of the targeting structure relative to the target space is then determined. The method further comprises capturing an image of a portion of the target space including the targeting structure and identifying the unique target pattern of one of the plurality facets visible in the captured image. The method also comprises establishing a pose of the mobile interface device relative to the target space using the captured image and the position of the targeting structure, obtaining AR information associated with the unique target pattern of the particular one of the plurality facets, and displaying the AR information on the mobile interface device. | 03-24-2016 |
Hunter Blanks, Oakland, CA US
Patent application number | Description | Published |
---|---|---|
20140280241 | Methods and Systems to Organize Media Items According to Similarity - Users collect digital media items such as songs, images, and videos into media libraries. Over time, the user can collect a very large number of media items making organization and use of the media library difficult and time-consuming. The systems and methods described herein alleviate this task by collecting metadata about the media items from multiple sources, determining a similarity between the media items, and clustering the media items with like media items. The systems and methods described herein can position the media items relative to one another in a layout based on their respective similarity. Feedback from the user and from other users can be added to the metadata and used to update the layout of the media items. | 09-18-2014 |
Janet Blanks, Boca Raton, FL US
Patent application number | Description | Published |
---|---|---|
20120295979 | USE OF SULINDAC FOR PROTECTING RETINAL PIGMENT EPITHELIAL CELLS AGAINST OXIDATIVE STRESS - Compositions and methods described herein are based on the use of the drug sulindac, a non steroidal anti-inflammatory drug (NSAID), for protecting retinal pigment epithelial cells against oxidative stress which is a major component of macular degeneration. Described herein is a new use for sulindac. | 11-22-2012 |
Janet C. Blanks, Boca Raton, FL US
Patent application number | Description | Published |
---|---|---|
20080305083 | GFAP-BASED GENE THERAPY FOR TREATMENT OF RETINAL DISEASES - Compositions and methods for reducing neovascularization. Purified nucleic acid constructs and vectors encoding an anti-angiogenic protein operably linked to a GFAP promoter. Vectors can include at least one hypoxia regulated element, enhancer element and silencer element. Gene therapy methods for reducing, delaying or preventing neovascularization based on the nucleic acid constructs and vectors. | 12-11-2008 |
20120077870 | Materials and Methods for the Treatment of Pathological Neovascularization in the Eye - The subject invention provides materials and methods useful in safely and effectively preventing pathological proliferation of blood vessels. The prevention of the over-proliferation of blood vessels according to the subject invention is particularly advantageous for treatment of certain ocular conditions including age-related macular degeneration (AMD), retinopathy of prematurity (ROP) and diabetic retinopathy. In preferred embodiments, the subject invention provides materials and methods for effective treatment of pathological ocular neovascularization using gene therapy. In a specific embodiment the materials and methods of the subject invention can be used to treat AMD. | 03-29-2012 |
20150080458 | Materials and Methods for the Treatment of Pathological Neovascularization in the Eye - The subject invention provides materials and methods useful in safely and effectively preventing pathological proliferation of blood vessels. The prevention of the over-proliferation of blood vessels according to the subject invention is particularly advantageous for treatment of certain ocular conditions including age-related macular degeneration (AMD), retinopathy of prematurity (ROP) and diabetic retinopathy. In preferred embodiments, the subject invention provides materials and methods for effective treatment of pathological ocular neovascularization using gene therapy. In a specific embodiment the materials and methods of the subject invention can be used to treat AMD. | 03-19-2015 |
20160074350 | Retinopathy Treatment - A method of preventing degeneration of photoreceptor cells in an eye of a mammalian subject includes the step of administering pharmaceutical composition comprising a sulindac agent to the eye of the subject. | 03-17-2016 |
Jeremy Daniel Blanks, Parkton, NC US
Patent application number | Description | Published |
---|---|---|
20140373409 | STRUCTURED WRAP AND METHOD OF USING SAME - A structured wrap includes an inner support member and a cover enclosing the support member. The wrap can be attached to a cylindrical, cubic, rectangular or similar object, such as a vehicle roof/luggage rack, rear spoiler or a standalone component, such as a fence or pole. The wrap can allow for advertising or promotion of personal interests, as well as protection of the rack or component itself from scratches or other damage from normal use. | 12-25-2014 |
Jessica Blanks, Fort Myers, FL US
Patent application number | Description | Published |
---|---|---|
20140273132 | Process for Inoculating a Bioreactor with Cyanobacteria - A process is described for the creation of an inoculum for an organism capable of photosynthesis of a target compound within a closed bioreactor, involving steps of transfer of a sterile growth medium under pressure without exposure to atmosphere. The process is useful for the creation of inocula for the growth of cyanobacteria to produce target chemical products, such as ethanol, in closed photobioreactors. | 09-18-2014 |
20140273175 | System for Staged Inoculation of Multiple Cyanobacterial Photobioreactors for Commercial Scale Generation of Cyanobacteria Cultures - A method of rapid simultaneous inoculation of cyanobacteria to multiple commercial-scale closed photobioreactors for the production of a target molecule such as ethanol. | 09-18-2014 |
20160024458 | Process For Inoculating Closed Photobioreactors With Cyanobacteria - Methods of inoculum scale-up of cyanobacteria to commercial-scale closed photobioreactors for the production of a target molecule such as ethanol. | 01-28-2016 |
Lataunya Lashea Blanks, Belleville, MI US
Patent application number | Description | Published |
---|---|---|
20120296494 | REMOTE OPERATOR ASSISTANCE FOR ONE OR MORE USER COMMANDS IN A VEHICLE - Various embodiments relate to remote operator assistance for one or more user commands at a vehicle. The operator assistance may occur via a vehicle computing system. One or more instances of an unsuccessful attempt to perform a user command may be received by the vehicle computing system. After detection of a predetermined number of instances, a connection may be established, via the vehicle computing system, with a remotely located system. The remotely-located system may be operated by a human operator in order to assist with performance of the user command. An information exchange may be facilitated between the vehicle and the remotely located system operated by the human operator. The information exchange may relate to the user command. The user command may be performed in the vehicle based on information obtained from the remotely-located system. | 11-22-2012 |
20130184898 | Remote Operator Assistance for One or More User Commands in a Vehicle - Various embodiments relate to remote operator assistance for one or more user commands at a vehicle. The operator assistance may occur via a vehicle computing system. One or more instances of an unsuccessful attempt to perform a user command may be received by the vehicle computing system. After detection of a predetermined number of instances, a connection may be established, via the vehicle computing system, with a remotely located system. The remotely-located system may be operated by a human operator in order to assist with performance of the user command. An information exchange may be facilitated between the vehicle and the remotely located system operated by the human operator. The information exchange may relate to the user command. The user command may be performed in the vehicle based on information obtained from the remotely-located system. | 07-18-2013 |
Robert C. Blanks, Auburndale, MA US
Patent application number | Description | Published |
---|---|---|
20120189720 | METHOD FOR TREATMENT OF DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME - The present invention provides methods for treating diarrhea-predominant irritable bowel syndrome comprising administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea-predominant irritable bowel syndrome (d-IBS). Treatment of d-IBS includes the treatment of the diarrhea component of d-IBS as well as the pain, abdominal discomfort and other symptoms associated with d-IBS. In one embodiment, the inhibitor of chloride-ion transport is crofelemer. | 07-26-2012 |
20120282298 | CORTICOSTEROIDS FOR THE TREATMENT OF JOINT PAIN - Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production. | 11-08-2012 |
20120288534 | Corticosteroids for the Treatment of Joint Pain - Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production. | 11-15-2012 |
20140242170 | Corticosteroids for the Treatment of Joint Pain - Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production. | 08-28-2014 |
20140356437 | Corticosteroids for the Treatment of Joint Pain - Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production. | 12-04-2014 |
20150025050 | Corticosteroids for the Treatment of Joint Pain - Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production. | 01-22-2015 |
20150050338 | METHOD FOR TREATMENT OF DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME - The present invention provides methods for treating diarrhea-predominant irritable bowel syndrome comprising administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea-predominant irritable bowel syndrome (d-IBS). Treatment of d-IBS includes the treatment of the diarrhea component of d-IBS as well as the pain, abdominal discomfort and other symptoms associated with d-IBS. In one embodiment, the inhibitor of chloride-ion transport is crofelemer. | 02-19-2015 |
Steven Blanks, Manchester GB
Patent application number | Description | Published |
---|---|---|
20080267686 | Marker System and Carrier Device - A marker carrier device has carrier elements for carrying respective markers, the device being re-configurable between a compact configuration and a selection configuration in which the markers are accessibly presented for selection. Carrier devices loaded with markers are received at a receiving station of a marking unit. The markers are selected from the carrier individually whilst in the marking unit and marked by a marking device with a predetermined indicium. | 10-30-2008 |
Steven Blanks, West Sussex GB
Patent application number | Description | Published |
---|---|---|
20110206442 | MARKER SYSTEM AND CARRIER DEVICE - A marker carrier device has carrier elements for carrying respective markers, the device being re-configurable between a compact configuration and a selection configuration in which the markers are accessibly presented for selection. Carrier devices loaded with markers are received at a receiving station of a marking unit. The markers are selected from the carrier individually whilst in the marking unit and marked by a marking device with a predetermined indicium. | 08-25-2011 |